RST 001

Drug Profile

RST 001

Alternative Names: RST-001

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Wayne State University
  • Developer RetroSense Therapeutics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Retinitis pigmentosa

Most Recent Events

  • 06 Sep 2016 Allergan acquires RST 001 from RetroSense Therapeutics
  • 30 Aug 2016 RetroSense Therapeutics has patent protection for the methods of restoring or improving vision using optogenetic approaches in USA
  • 01 Nov 2015 Phase-I/II clinical trials in Retinitis pigmentosa in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top